The researchers intend to use the current findings "in support of an FDA application potentially to allow an indication for the use of hydroxyurea in very young children," Dr. Rogers said. "We are also hoping that there will be an interest for the use of this medication in a liquid format, because it’s very hard to get a 1-year-old to take a capsule."
The follow-up study is funded by the National Heart, Lung, and Blood Institute and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.